0000000000129198

AUTHOR

Marcus Hacker

showing 2 related works from this author

Comparison of MRI and VQ-SPECT as a Screening Test for Patients With Suspected CTEPH: CHANGE-MRI Study Design and Rationale

2020

The diagnostic strategy for chronic thromboembolic pulmonary hypertension (CTEPH) is composed of two components required for a diagnosis of CTEPH: the presence of chronic pulmonary embolism and an elevated pulmonary artery pressure. The current guidelines require that ventilation–perfusion single-photon emission computed tomography (VQ-SPECT) is used for the first step diagnosis of chronic pulmonary embolism. However, VQ-SPECT exposes patients to ionizing radiation in a radiation sensitive population. The prospective, multicenter, comparative phase III diagnostic trial CTEPH diagnosis Europe - MRI (CHANGE-MRI, ClinicalTrials.gov identifier NCT02791282) aims to demonstrate whether functional…

VQ-SPECT0301 basic medicinelcsh:Diseases of the circulatory (Cardiovascular) systemmedicine.medical_specialtypulmonary embolismElevated pulmonary artery pressurePHCTEPHPopulationCardiovascular Medicine030204 cardiovascular system & hematologyMri ; Vq-spect ; Cteph ; Ph ; Pulmonary Embolism ; Diagnostic Strategydiagnostic strategyStudy Protocol03 medical and health sciences0302 clinical medicinemedicine.arteryPulmonary angiographyMedicineeducationeducation.field_of_studymedicine.diagnostic_testbusiness.industryDiagnostic TrialGold standard (test)medicine.disease3. Good healthPulmonary embolism030104 developmental biologylcsh:RC666-701Pulmonary arteryRadiologyCardiology and Cardiovascular MedicinebusinessEmission computed tomographyMRIFrontiers in Cardiovascular Medicine
researchProduct

Multiparametric 18F-FDG PET-MRI of the breast: are there differences in imaging biomarkers of contralateral healthy tissue between patients with and …

2019

The rationale was to assess whether there are differences in multiparametric 18F-FDG PET/MRI biomarkers of contralateral healthy breast tissue in patients with benign and malignant breast tumors. Methods: In this institutional review board-approved prospective single-institution study, 141 women with imaging abnormalities on mammography or sonography (BI-RADS 4/5) underwent combined 18F-FDG PET/MRI of the breast at 3T with dynamic contrast-enhanced MRI, diffusion-weighted imaging, and the radiotracer 18F-FDG. In all patients, the following imaging biomarkers were recorded for the contralateral (tumor-free) breast: breast parenchymal uptake (BPU) (from 18F-FDG PET), mean apparent diffusion c…

medicine.medical_specialtyImaging biomarkerdiffusion-weighted imagingMalignancy030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineBreast cancerbreast cancerF-18-FDG PET/MRImedicineMammographyEffective diffusion coefficientF-18-FDG PET/MRI breast cancer; dynamic contrast-enhanced MRI diffusion-weighted imaging imaging biomarkerimaging biomarkerRadiology Nuclear Medicine and imagingdynamic contrast-enhanced MRImedicine.diagnostic_testbusiness.industryCancermedicine.disease030220 oncology & carcinogenesisDynamic contrast-enhanced MRIRadiologybusinessDiffusion MRI
researchProduct